Cagrlintide is a novel long-acting acylated amylin analogue under development, primarily used as a non selective agonist of amylin receptor (AMYR) and calcitonin G protein coupled receptor (CTR). Cagralintide significantly reduces food intake and weight loss by activating these receptors, demonstrating its potential in obesity research
